» Articles » PMID: 37842043

HtrA3: a Promising Prognostic Biomarker and Therapeutic Target for Head and Neck Squamous Cell Carcinoma

Overview
Journal PeerJ
Date 2023 Oct 16
PMID 37842043
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The dysregulation of the human high-temperature requirement A (HtrA) family of serine proteases is associated with many malignancies. However, there are few reports on HtrAs in head and neck squamous cell carcinoma (HNSCC). The aim of this study was to investigate the expression, prognostic value, and biological functions of HtrAs in HNSCC.

Methods: The RNA-sequencing data and clinical data of HNSCC were downloaded from The Cancer Genome Atlas (TCGA) database. The GSE30784 and GSE31056 datasets from the Gene Expression Omnibus (GEO) database were used for further verification. This study explored the differential expression of HtrAs and assessed their potential impact on the prognosis of HNSCC patients using a survival module. Correlations between clinical characteristics and HtrA expression levels were then explored using a Wilcoxon rank sum test. A Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) were performed using "clusterProfile" in the R software. A Pearson/Spearman correlation test was applied to analyze the relationship between HtrAs and immune infiltration level/checkpoint genes. Validation of HtrA expression levels were carried out by RT-PCR and western blot in human squamous carcinoma cell lines (Fadu and Cal-27) and human non-tumorigenic bronchial epithelium cells (BEAS-2B). Finally, through cell transfection, CCK-8, Ki-67 immunofluorescence, and flow cytometry assays, the effect of HtrA3 knockdown on the malignant biological behavior of HNSCC cells was explored.

Results: The gene expression levels of HtrAs were significantly upregulated and associated with patient age, TNM stage, clinical stage, and TP53 mutation status in the TCGA-HNSCC cohort. High expressions of HtrA1/3 were associated with shorter overall survival, shorter progress-free interval, and lower disease-specific survival in HNSCC. A nomogram for HtrAs was constructed and validated. HtrA-related genes were significantly enriched in the immune response and cell apoptosis pathway. In addition, the expression of HtrAs showed significant correlations with B cells, M cells, DC cell infiltration, and immune infiltration checkpoint (CD276, TNFRSF14). Validation of HtrA expression was carried out by RT-PCR and western blot. Results of experiments indicated that HtrA3 gene knockdown inhibits the proliferation of FaDu and Cal-27 cells while concurrently promoting apoptosis.

Conclusions: HtrA3 shows significant potential as both a prognostic marker and a promising therapeutic target for HNSCC, highlighting its relevance and importance in future research and potential clinical applications.

Citing Articles

SCGB1A1 as a novel biomarker and promising therapeutic target for the management of HNSCC.

Wang J, Xu Q, Yu J, Xu A, Yu L, Chen Z Oncol Lett. 2024; 28(5):527.

PMID: 39268163 PMC: 11391500. DOI: 10.3892/ol.2024.14660.


The Art of Finding the Right Drug Target: Emerging Methods and Strategies.

Jia Z, Yang X, Wu Y, Li M, Das D, Chen M Pharmacol Rev. 2024; 76(5):896-914.

PMID: 38866560 PMC: 11334170. DOI: 10.1124/pharmrev.123.001028.


Exploring the Role of HtrA Family Genes in Cancer: A Systematic Review.

Rosochowicz M, Kulcenty K, Suchorska W Mol Diagn Ther. 2024; 28(4):347-377.

PMID: 38717523 PMC: 11211202. DOI: 10.1007/s40291-024-00712-2.

References
1.
Wang R, Dai W, Gong J, Huang M, Hu T, Li H . Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients. J Hematol Oncol. 2022; 15(1):11. PMC: 8785554. DOI: 10.1186/s13045-022-01225-3. View

2.
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

3.
Gillison M, Chaturvedi A, Anderson W, Fakhry C . Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015; 33(29):3235-42. PMC: 4979086. DOI: 10.1200/JCO.2015.61.6995. View

4.
Ellis M, Gillette M, Carr S, Paulovich A, Smith R, Rodland K . Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov. 2013; 3(10):1108-12. PMC: 3800055. DOI: 10.1158/2159-8290.CD-13-0219. View

5.
Xu Z, Chen X, Peng C, Liu E, Li Y, Li C . Hypoxia-inducible factor-1alpha suppressed hepatocellular carcinoma cell apoptosis through influencing on Omi/HtrA2 expression and its releasing from the mitochondrion. Oncol Res. 2013; 20(5-6):213-20. DOI: 10.3727/096504013x13589503482815. View